Could ENDRA Life Sciences Inc. (NDRA) See a Reversal After This Very Strong Session?

December 7, 2017 - By Michael Collier

The stock of ENDRA Life Sciences Inc. (NASDAQ:NDRA) is a huge mover today! The stock increased 4.84% or $0.19 during the last trading session, reaching $4.03. About 63,681 shares traded or 557.18% up from the average. ENDRA Life Sciences Inc. (NASDAQ:NDRA) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.
The move comes after 6 months positive chart setup for the $15.75 million company. It was reported on Dec, 7 by We have $4.35 PT which if reached, will make NASDAQ:NDRA worth $1.26M more.

More notable recent ENDRA Life Sciences Inc. (NASDAQ:NDRA) news were published by: which released: “ENDRA Announces Partnership to Accelerate Development of ENDRA’s Clinical …” on May 23, 2016, also with their article: “Endra Seeks $11 Million IPO For TAEUS Commercialization” published on December 10, 2016, published: “ENDRA Life Sciences Adds Nexus 128+ to Their 3D Preclinical Photoacoustic CT …” on September 01, 2016. More interesting news about ENDRA Life Sciences Inc. (NASDAQ:NDRA) were released by: and their article: “ENDRA Life Sciences Prices IPO at $5/Unit (NDRAU) (NDRA) (NDRAW)” published on May 09, 2017 as well as‘s news article titled: “ENDRA Life Sciences Inc. (NASDAQ: NDRA) to Ring The Nasdaq Stock Market …” with publication date: July 06, 2017.

ENDRA Life Sciences Inc. develops photo- and thermo-acoustic medical technologies that bring new capabilities to existing ultrasound systems. The company has market cap of $15.75 million. The Company’s photo-acoustic solutions help global medical researchers to screen and modify disease models with high image quality and volume scanning speed. It currently has negative earnings. The firm offers the Nexus-128 system, a fully 3D imaging solution for imaging anatomy, physiology, and labeled molecular targets for institutions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.